Takeda's Entyvio disease-clearance strategy cuts ulcerative colitis complication risk nearly 70% in trial

• Takeda announced Phase 4 VERDICT results showing Entyvio targeting disease clearance delayed ulcerative colitis complications compared with targeting symptom remission alone.
• Disease clearance combines steroid-free symptom remission with visible and microscopic intestinal healing in adults with moderate to severe ulcerative colitis.
• No new safety signals emerged through 96 weeks; adverse event rates were similar across treatment-target groups.
• Results were presented at United European Gastroenterology Week 2026 and published in the United European Gastroenterology Journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190530BIZWIRE_USPR_____20261019_BW826127) on October 19, 2026, and is solely responsible for the information contained therein.